We narrowed to 26,706 results for: vit;

#100854-AAV9

Ready-to-use AAV9 particles produced from pAAV.Syn.NES-jRGECO1a.WPRE.SV40 (#100854). In addition to the viral particles, you will also receive purified pAAV.Syn.NES-jRGECO1a.WPRE.SV40 plasmid DNA. Synapsin-driven GECO1a calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

April 17, 2018

Academic Institutions and Nonprofits only

#140554-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA2h (#140554). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA2h plasmid DNA. Synapsin-driven expression of high-affinity GRAB_DA2h dopamine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 9, 2021

Academic Institutions and Nonprofits only

#140553-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA2m (#140553). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA2m plasmid DNA. Synapsin-driven expression of 2nd generation medium affinity dopamine sensor GRAB_rDA2m. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#100853-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.Flex.NES-jRGECO1a.WPRE.SV40 (#100853). In addition to the viral particles, you will also receive purified pAAV.Syn.Flex.NES-jRGECO1a.WPRE.SV40 plasmid DNA. Synapsin-driven, Cre-dependent GECO1a calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

Feb. 28, 2018

Academic Institutions and Nonprofits only

#100851-AAV9

Ready-to-use AAV9 particles produced from pAAV.Syn.NES-jRCaMP1b.WPRE.SV40 (#100851). In addition to the viral particles, you will also receive purified pAAV.Syn.NES-jRCaMP1b.WPRE.SV40 plasmid DNA. Syn-driven jRCaMP1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

April 13, 2018

Academic Institutions and Nonprofits only

#140556-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_rDA1m (#140556). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_rDA1m plasmid DNA. Synapsin-driven expression of red fluorescent medium affinity dopamine sensor GRAB_rDA1m. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#99039-AAV5

Ready-to-use AAV5 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 21, 2018

Academic Institutions and Nonprofits only

#112010-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSynapsin1-FLEx-axon-GCaMP6s (#112010). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-FLEx-axon-GCaMP6s plasmid DNA. Synapsin-driven, cre-dependent axon targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Dec. 4, 2018

Academic Institutions and Nonprofits only

#112010-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-FLEx-axon-GCaMP6s (#112010). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-FLEx-axon-GCaMP6s plasmid DNA. Synapsin-driven, cre-dependent axon-targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

April 2, 2019

Academic Institutions and Nonprofits only

#100852-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.NES-jRGECO1a.WPRE.SV40 (#100852). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.NES-jRGECO1a.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent jRGECO1a calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

July 23, 2018

Academic Institutions and Nonprofits only

#58880-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA. Humanized channelrhodopsin H134R mutant fused to GFP, under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Boyden et al Nat Neurosci. 2005 Sep . 8(9):1263-8.

June 20, 2017

Academic Institutions and Nonprofits only

#128434-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-tdTomato (#128434). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-tdTomato plasmid DNA. EF1a-driven, Flp-dependent expression of tdTomato. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

March 12, 2021

Academic Institutions and Nonprofits only

#100850-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.Flex.NES-jRCaMP1b.WPRE.SV40 (#100850). In addition to the viral particles, you will also receive purified pAAV.Syn.Flex.NES-jRCaMP1b.WPRE.SV40 plasmid DNA. Syn-driven, Cre-dependent NES-jRCaMP1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 11, 2018

Academic Institutions and Nonprofits only

#100851-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.NES-jRCaMP1b.WPRE.SV40 (#100851). In addition to the viral particles, you will also receive purified pAAV.Syn.NES-jRCaMP1b.WPRE.SV40 plasmid DNA. Syn-driven jRCaMP1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

April 13, 2018

Academic Institutions and Nonprofits only

#100846-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.NES-jRCaMP1a.WPRE.SV40 (#100846). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.NES-jRCaMP1a.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent jRCaMP1a calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 11, 2018

Academic Institutions and Nonprofits only

#140557-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_rDA1h (#140557). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_rDA1h plasmid DNA. Synapsin-driven expression of red fluorescent, high affinity dopamine sensor GRAB_rDA1h. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#100849-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.NES-jRCaMP1b.WPRE.SV40 (#100849). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.NES-jRCaMP1b.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent NES-jRCaMP1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 11, 2018

Academic Institutions and Nonprofits only

#99039-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#153286-AAV2

Ready-to-use AAV2 particles produced from pAAV-hsyn-GRAB_Ado1.0med (#153286). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_Ado1.0med plasmid DNA. Synapsin-driven expression of GRAB_Ado1.0med adenosine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Wu et al Proc Natl Acad Sci U S A. 2023 Apr 4;120

Nov. 13, 2025

Academic Institutions and Nonprofits only

#247028

Enriched for effective guides through prioritization of guides with strong on-target activity. Designed against current gene annotations, offering coverage of the contemporary mouse genome.

John Doench, David Root

Drepanos et al bioRxiv 2025.08.26.672375; doi: https://

Oct. 2, 2025

Academic Institutions and Nonprofits only

#171027-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

June 26, 2024

Academic Institutions and Nonprofits only

#108912-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-ChroME-ST-P2A-H2B-mRuby3 (#108912). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-ChroME-ST-P2A-H2B-mRuby3 plasmid DNA. CAG-driven, Cre-dependent ChroME-ST-P2A-H2B-mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

Hillel Adesnik

Mardinly et al Nat Neurosci. 2018 Apr 30. pii: 10.1038/

Nov. 20, 2018

Academic Institutions and Nonprofits only

#28305-AAV5

Ready-to-use AAV5 particles produced from pAAV-FLEX-ArchT-tdTomato (#28305). In addition to the viral particles, you will also receive purified pAAV-FLEX-ArchT-tdTomato plasmid DNA. CAG-driven Cre-dependent ArchT-tdTomato expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#171027-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

July 21, 2023

Academic Institutions and Nonprofits only

#84471-AAV8

Ready-to-use AAV8 particles produced from pAAV-RAM-d2TTA::TRE-ChR2-WPREpA (#84471). In addition to the viral particles, you will also receive purified pAAV-RAM-d2TTA::TRE-ChR2-WPREpA plasmid DNA. RAM-containing and TRE-driven, ChR2 H134R mutant fused to EYFP. These AAV preparations are suitable purity for injection into animals.

Yingxi Lin

Sorensen et al Elife. 2016 Sep 23;5. pii: e13918. doi:

Jan. 15, 2026

Academic Institutions and Nonprofits only

#112005-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 (#112005). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and mRuby3 expression. The mRuby3 will be a separate protein (not a fusion protein). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

April 24, 2019

Academic Institutions and Nonprofits only

#140555-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA-mut (#140555). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA-mut plasmid DNA. Synapsin-driven expression of control dopamine sensor GRAB_DA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#112005-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 (#112005). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and mRuby3 expression. The mRuby3 will be a separate protein (not a fusion protein). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Dec. 4, 2018

Academic Institutions and Nonprofits only

#140558-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_rDA-mut (#140558). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_rDA-mut plasmid DNA. Synapsin-driven expression of control red fluorescent dopamine sensor GRAB_rDA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#112004-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 (#112004). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and bicistronic mKate2 expression. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Feb. 14, 2022

Academic Institutions and Nonprofits only